Agenus (AGEN)
(Delayed Data from NSDQ)
$5.09 USD
-0.19 (-3.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.07 -0.02 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Brokerage Reports
Agenus Inc. [AGEN]
Reports for Purchase
Showing records 221 - 240 ( 260 total )
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Meeting With Management - Adjuvants and Vaccines to Drive Value
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Meeting With Management - Adjuvants and Vaccines to Drive Value
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DERISKED PHASE 3 ASSET IN HANDS OF MARQUEE PARTNERS
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DERISKED PHASE 3 ASSET IN HANDS OF MARQUEE PARTNERS
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Partnered Programs Step Closer to the Finish
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2Q11 results in line - highlighted by encouraging G-200 results at ASCO
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Building on Encouraging G-200 Results at ASCO
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Highlights Increasing Survival Benefit in Glioma - Phase 3 to Start 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Highlights Increasing Survival Benefit in Glioma - Phase 3 to Start 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with a Buy Rating and Price Target of $2
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q11 - QS-21 ROYALTIES A NEAR TERM VALUE DRIVER ? UPGRADING TO OUTPERFORM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q11 - QS-21 ROYALTIES A NEAR TERM VALUE DRIVER - UPGRADING TO OUTPERFORM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
4Q10 UPDATE - A NEW NAME - A NEW FOCUS -"A GENIUS" STRATEGY
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
4Q10 UPDATE- A NEW NAME- A NEW FOCUS-"A GENIUS"STRATEGY
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.